Although cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), is defined as a “targeted therapy”, its use has not been restricted to tumors with proven expression of the target, because the vast majority of squamous cell carcinomas of the head and neck is characterized by EGFR amplification (2). Here, EGFR is linked to squamous cell carcinoma.